Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
[1] [12] Additionally, GLP-1 receptor agonists slow gastric emptying and act on appetite centres in the brain, promoting satiety and reducing food intake
GLP-1 Receptor Glucagon-like peptide-1 receptor, a protein found in pancreas, brain, stomach, and other tissues
Probing human sperm metabolism using 13 C-magnetic resonance spectroscopy
Copper toxicity concerns are generally minimal with topical applications due to limited systemic absorption
Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment
US$ 27.92
US$ 28.80
US$ 22.17
US$ 20.30
US$ 29.40
